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Abstract 
 
Background 
 
Contrast enhanced echocardiography (CEE) is utilised when sub-optimal 
image quality results in non-diagnostic echocardiograms. However, there 
have been numerous safety notices issued by regulatory authorities regarding 
rare but potentially serious adverse reactions (AR). This multi-centre, 
retrospective analysis was performed to assess the short-term safety of CEE 
in a broad range of indications. 
 
Methods 
 
All CEE performed over 58 months at three institutions were assessed for AR 
within 30 minutes. 
 
Results 
 
5956 CEE were performed in 5576 patients. 4903 were stress CEE and 1053 
resting CCE.  Bolus administration in 5719, infusion in 237 cases. 88.9% of 
CCE were outpatients. Commonest CEE indication was functional stress 
testing (82.3%).  There were 16 AR related to CEE (0.27%). All AR were mild, 
transient and all patients made a full recovery. No cases of serious 
anaphylaxis or death within 30 minutes of contrast administration.  Comparing 
those with and without an AR, there were no significant differences in age, 
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gender, BMI, LVEF, patient location, exam type or RVSP. There was a slightly 
increased likelihood of an AR during infusion versus bolus dosing (p=0.02).  
 
Conclusion 
 
CEE is a safe investigation in a broad range of indications and clinical 
scenarios. AR are very rare, mild and transient.  
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Introduction 
 
Transthoracic echocardiography (TTE) is a safe, non-invasive bedside 
imaging technique that provides comprehensive information regarding cardiac 
structure and function. It is the most frequently used cardiac imaging modality. 
However, in up to 25% of cases suboptimal images are obtained (1-4). This 
may be due to body habitus, lung disease or a difficult scanning environment, 
such as in the critical care complex where lighting, patient position and 
mechanical ventilation can all hinder acquisition of diagnostic TTE images. 
The administration of an echocardiographic contrast agent, when coupled with 
contrast specific imaging modalities, offers the ability to salvage and convert 
these non-diagnostic scans into diagnostic echocardiograms (5-11).  
 
Although these agents have been in clinical use for over a decade, in 2007 
the American Food and Drug Administration (FDA) and European Medicines 
Agency (EMEA) issued a “boxed warning” regarding their safety profile (12, 
13). Whilst this warning has subsequently been downgraded on two separate 
occasions, there still remains a perception these agents may have a 
significant adverse event profile, which could unduly influence 
recommendations for their use. This retrospective analysis was performed to 
assess the short term safety of the perflutren microsphere contrast agent 
Definity® (Lantheus Medical Imaging, North Billerica, MA, USA)  during both 
resting and stress echocardiography, at three different institutions. 
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Material and Methods 
 
A retrospective analysis of all contrast echocardiograms using Definity® at 
three institutions in Queensland, Australia (Greenslopes Private Hospital, The 
Prince Charles Hospital (TPCH) and Caboolture Hospital) was performed. A 
database search of all reports written for contrast echocardiograms was 
undertaken and the necessary information derived from these reports. 
Contrast use was based upon conventional indications to enhance image 
quality or where the supervising cardiologist determined that contrast 
administration would improve their confidence in image interpretation. 
Contrast was administered either as a diluted bolus or an infusion. Bolus 
dosing was performed by diluting one activated ampoule of Definity® contrast 
with 10 to 30 mL. of normal saline and slowly injecting 0.5 - 1.0 mL aliquots. 
Infusion dosing was performed by diluting one activated ampoule of Definity® 
contrast to 50 mL with normal saline and infusing at a rate between 150 and 
300 mL/hour, to optimise image quality. 
 
Resting contrast echocardiograms were performed in the standard manner 
with contrast specific, low mechanical index imaging techniques during 
Definity® administration. Dobutamine stress echocardiograms (DSE) were 
performed in a conventional manner with incremental increases in 
dobutamine every 3 minutes (from 5mcg/kg/min to 40 mcg/kg/min infusion 
rates) and intravenous atropine if required, to achieve a target heart rate of 
85% of maximum predicted for age. Definity® was administered at each stage 
where echocardiographic imaging was required. For contrast exercise stress 
 9
echocardiograms (ESE), Definity® was administered at baseline and just prior 
to image acquisition at peak stress. 
 
Conventional patient demographics were collected as well as the following 
parameters: method of contrast administration (diluted bolus or infusion), type 
of echocardiogram (rest or stress), indication for contrast imaging, patient 
location (in-patient or outpatient), presence of any adverse event, severity of 
adverse event, impact of adverse event upon test continuation, left ventricular 
ejection fraction (LVEF) and right ventricular systolic pressure (RVSP).  
During stress echocardiography (where the chosen stressor could also induce 
an adverse reaction), the supervising clinician reported whether the AR was 
thought due to contrast or the method of stress. Additionally, during the 
course of this analysis, the requirement for formal monitoring in patients 
following contrast administration varied.  However, all patients were under 
medical supervision for at least 30 minutes after initiation of contrast 
administration.  
 
Continuous variables were expressed as a mean, ±1 standard deviation and 
range. Categorical variables were expressed as a frequency and percentage 
proportion. Comparison between 2 groups (adverse event versus no adverse 
event) was performed using the 2 sample student’s t test for continuous 
variables and chi-square tests for categorical variables. A p value of <0.05 
was considered as statistically significant. All statistical analyses were 
performed using MedCalc® version 12.3 (Mariakerke, Belgium). Approval for 
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publication of this article was obtained from the Research, Ethics and 
Governance Unit at The Prince Charles Hospital. 
 
Results 
 
A total of 5956 contrast echocardiograms were performed in 5576 patients 
between August 2007 and May 2012. All patients received Definity® contrast 
as no alternative contrast agent was commercially available in Australia. 5354 
contrast cases (88.9%) were out-patients and 602 (11.1%) were performed as 
an in-patient basis. 211 of the inpatients (35%) were in the critical care 
complex (153 in the coronary care complex and 58 in the intensive care unit). 
Table 1 lists the patient demographics and echocardiographic characteristics 
for all contrast echocardiograms. 
 
There were a total of 16 adverse events (0.27%) attributed to contrast 
administration (9 females, 7 males). Adverse events occurred with 4 resting 
TTE (0.37%), 7 DSE (0.94%), and 5 ESE (0.12%). The adverse events 
attributed to contrast administration are listed in table 2. All adverse events 
were mild and brief with all patients making a full recovery. There were no 
acute life threatening adverse events or severe anaphylaxis. There were no 
deaths within 30 minutes of contrast administration. 
 
Patient and echocardiographic characteristics for those contrast 
echocardiograms with an adverse event are summarised in Table 3. There 
was only one adverse event (mild facial flushing) reported in the 211 contrast 
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studies performed on patients within the critical care complex. Adverse events 
occurred in 13/5719 diluted bolus dosing (0.2%)  and 3/237 during an infusion 
administration of contrast (1.3%). Continuation of the contrast 
echocardiogram was possible in all but 3 cases (81%) despite the presence of 
an adverse event. The associated co-mordities in those patients who had a 
contrast AR were dyslipidemia (10), hypertension (9), known drug allergy (8), 
prior myocardial infarction (5), diabetes mellitus (3), systemic lupus 
erythematosus (1), hypothyroidism (1), lymphoma (1) and atrial fibrillation (1). 
 
There were no significant differences in age, body mass index (BMI), LVEF or 
RVSP between those who had a contrast reaction compared to those who did 
not.  There was no significant difference in gender, patient location (in-patient 
versus out-patient) or exam type (resting TTE versus stress TTE) between 
those who did and those who did not have an adverse reaction. However, 
patients receiving infusion dosing were more likely to have an adverse 
reaction than those who has bolus administration (p=0.02). 
 
A small proportion of patients with a mechanical cardiac support device had a 
contrast enhanced TTE (n=10). 6 were supported by extra-corporal 
membrane oxygenation, 2 by a pulsatile left ventricular assist device and two 
by an intra-aortic balloon pump. There were no adverse reactions in any of 
these patients. There were no alterations in their cardio-respiratory 
parameters or in function of the mechanical support device during or within 30 
minutes of contrast administration. 
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Discussion 
 
The results of this study add to the increasing body of evidence that highlights 
the low adverse event rate associated with perflutren microsphere contrast 
echocardiography in a broad range of clinical indications and patient 
populations. The cohorts in this analysis had a wide range of cardiac 
pathologies, with LVEF to below 10%  and pulmonary pressures above 60 
mmHg (maximum of 100 mmHg).The acute adverse event rate was very low. 
Patient clinical characteristics that have previously been suggested to 
increase the risk of an adverse reaction (such as left ventricular systolic 
dysfunction, increased body mass index and pulmonary hypertension), were 
not shown to increase the likelihood of an event. In those who did have an 
acute adverse event, these were all mild and transient. Additionally, in the 
majority of those who did have an adverse event, the severity was such that it 
did not prevent completion of the investigation in most cases. The overall 
majority of adverse reactions occurred during bolus dosing (81%). However, 
proportionally, there was a higher likelihood of an adverse reaction during 
infusion dosing compared to bolus administration (1.3% versus 0.2%, p=0.02). 
This was a surprising result as it may be plausible that the risk of an adverse 
reaction may be related to the actual contrast concentration, as suggested by 
previous research (14, 15). However, serious AR related to contrast are 
postulated to be complement activation-related pseudoallergy (CARPA) (15, 
16)     
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In our analysis, there were no serious AR, so it is difficult to summise a 
mechanism for a slight increase in AR due to infusion administration. In light 
of the low number of infusions compared to bolus dosing, firm conclusions 
regarding this cannot be made. However, with the overall adverse event rate 
of contrast echocardiography being so low, a study powered to detect a 
significant difference between administration methods could be difficult to 
perform. Additionally, considering the strength of evidence regarding safety of 
contrast, it is unlikely to be undertaken. 
 
Following approval of microsphere contrast agents for cardiac imaging by the 
FDA, initially in 1997 with Optison™ followed by Definity® in 2001, post 
marketing surveillance suggested a temporal relationship with a very small 
number of deaths within 30 minutes of the administration of Definity®. In light 
of this, the FDA then issued a “boxed” warning for microsphere contrast 
agents and updated their prescribing information in October 2007 (12). This 
stated that contrast was contraindicated in patients with serious 
cardiopulmonary conditions, mandated physiologic monitoring for 30 minutes 
after administration (rhythm and oxygen saturation monitoring) and stated 
that” the safety and efficacy of contrast with exercise or pharmacologic stress 
testing have not been established”. 
 
This boxed warning impacted upon contrast usage and resulted in significant 
concern within the echocardiographic community, especially considering 
patients most likely to benefit from contrast imaging were no longer deemed 
eligible to be scanned (17-19). As such, there was heightened awareness to 
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assess the safety of  these agents, with completion of numerous single centre 
and multicentre trials reviewing their safety. Following the collection of this 
safety data, the FDA downgraded their safety concerns in May 2008. The new 
contraindication added in October 2007 was then removed. The blanket 
requirement for monitoring in all patients following contrast administration was 
also reduced to only those patients with pulmonary hypertension or unstable 
cardiopulmonary syndromes. Again in October 2011, 4 years after the initial 
warnings, the FDA further downgraded their label changes for contrast 
echocardiography. The requirement for monitoring the patient after contrast 
administration was removed completely, the statement inserted in October 
2007, “the safety and efficacy of contrast with exercise or pharmacologic 
stress testing have not been established” was removed and clarification of 
serious reactions was achieved by inserting the phrases; “most serious 
reactions occur within 30 minutes of administration” and “serious 
cardiopulmonary reactions, including fatalities, have occurred uncommonly 
during or flowing perflutren-containing microsphere administration”. 
 
The structural principles of contrast microbubbles and their pharmacokinetic 
profile lend themselves to being safe and well tolerated agents. These agents 
act as intravascular flow and volume tracers (20). Unlike nuclear tracers and 
contrast enhanced magnetic resonance imaging, these ultrasound 
microbubbles do not undergo any metabolism or cellular uptake (19). 
Following administration, micro-bubbles usually persist for several minutes 
and are then broken down. The gaseous core consists of a high molecular 
weight, biologically inert gas which is rapidly excreted in the lungs. The lipid 
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shell is metabolised in a conventional manner. There is no known mechanism 
for a toxic or adverse effect. The risk of anaphylaxis with microsphere contrast 
administration is approximately 1/10,000.  This usually occurs within a few 
minutes of contrast administration. This may be due to a type 1 
hypersensitivity reaction labelled complement activation related pseudoallergy  
(CARPA). 
 
In light of the concern regarding contrast use in high risk and critically ill 
patients, Exuzides et al assessed the acute mortality of these patients who 
had an echocardiogram with and without contrast (21). Using propensity score 
matching, 2900 critically unwell patients who received Optison™ were 
compared with matched control patients. There was no increase in same day 
mortality in the critically unwell patient if they received contrast (odds ratio 
1.18; 95% confidence interval: 0.82 - 1.71; p=0.37). Kusnetzky et al also 
found that there was no increased mortality in hospitalised patients who 
received Definity® (22). This retrospective analysis compared in-patients who 
had an unenhanced TTE (n=12,475) to those in-patients who had a Definity® 
contrast TTE (n=6,196). There was no significant difference in the 24 hour 
mortality between the 2 groups (46 versus 26 deaths respectively, p=0.60). 
This was despite the contrast group having more significant co-morbidities 
and being more acutely unwell. There were no deaths within the first hour 
after any TTE. Main et al (23) provided further data on the acute mortality of 
in-patients who had a TTE, either with (n=58,254) or without a contrast agent 
(n=4,242,712). This retrospective analysis assessed the 24 hour mortality of 
both groups and found no significant difference between the two. The 1 day 
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mortality after an unenhanced TTE was 1.08% (45,789 deaths) and 1.06% 
(616 deaths) in the contrast TTE group (p=0.613). Additionally, multivariate 
logistic regression analysis revealed that patients who had a contrast TTE 
were 24% less likely to die in the first 24 hours than those who had an 
unenhanced TTE (odds ratio=0.76, 95% confidence interval 0.70 - 0.82).  
 
In our cohort, 211 patients in the coronary care unit or intensive care unit 
received contrast. Despite the acuity or severity of their illness to mandate this 
level of care, there was only one adverse event in this patient group (mild 
facial flushing). In light of the mild AR in the unwell patients within the critical 
care complex and potential for incremental bedside diagnostic information, the 
clinician should not consider performance of CE within the critical care 
complex to be contra-indicated. There is little published work specifically 
assessing contrast administration in patients on mechanical cardiac support 
(MCS) (24, 25). Whilst there were only 10 patients on MCS in this cohort, 
there were no adverse events in any of these patients. The incremental 
benefit of contrast enhanced TTE in these patients may also be the highest 
due to their clinical state, potential limitation in mobility and inability to have 
alternative imaging such as a cardiac MRI scan. These studies suggest that 
contrast should not be considered contraindicated in unwell patients. 
 
Another subgroup of patients in whom contrast echocardiography was thought 
to be of higher risk was those with pulmonary hypertension due to the 
potential of contrast microbubbles causing direct obstruction of the pulmonary 
microvasculature or alterations in pulmonary vasomotor activity, resulting in 
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pulmonary vasoconstriction. Both events could possibly cause an acute 
increase in the pulmonary artery pressure and right heart failure. The 
pharmacokinetic profile of Definity reveals that elimination of the gaseous core 
is similar between normal patients and those with chronic airflow limitation 
(1.3 minutes versus 1.9 minutes respectively) (26). Two recently published 
studies specifically analysing the safety of contrast TTE in the setting of 
pulmonary hypertension did not demonstrate a higher adverse event rate in 
those with elevated pulmonary pressures (27, 28). 
 
The CaRES (Contrast Echocardiography Registry for Safety Surveillance) trial 
by Weiss et al, was a prospective, multicentre, phase 4 surveillance registry 
study performed to assess the safety of Definity administration during rest and 
stress TTE (29). 1053 patients received Definity®, had cardio-respiratory 
monitoring for 30 minutes and attended telephone follow-up at 24 hours. 
There were no deaths, serious adverse events or significant adverse events 
following Definity® administration at 30 minutes or at 24 hours follow-up. The 
adverse event rate related to Definity® was 3.5%, with the majority of these 
categorised and either mild or moderate in severity. The authors of this FDA 
initiated study concluded that Definity® use in routine clinical practice is safe 
and well tolerated. 
 
In our study, stress echocardiography with both exercise and pharmacological 
stress, using contrast had a very low AR rate of 0.2%. In light of the induced 
physiological changes and possible ischaemia, the safety of contrast agents 
has been extensively evaluated in this setting. Gabriel at al reviewed 4786 
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patients (exercise stress=2,764 and dobutamine stress=2022) who has stress 
echocardiography with Definity® (approximately 60%) and Optison™ and 
compared the outcomes with a matched control group of 5,012 patients who 
did not receive a contrast agent (30). Compared to the controls, there was no 
significant difference with the contrast group for death within 24 hours, cardiac 
arrest, sustained ventricular tachycardia or other serious adverse events. 
Abdelmoneim et al compared 10,792 patients who received contrast during 
stress echocardiography (Definity®=9,281, Optison™=1,511) and 15,982 who 
did not require contrast (31). The end points of death and myocardial 
infarction were assessed at ≤72 hours, ≤30 days and out to 4.5 years. There 
was no increased risk of these end points if contrast was used. The adverse 
event rate related to contrast was1.3% (back pain=0.62%, headache 0.52%, 
both in 0.13% and wheeze in 0.03%). 
 
Dolan et al reviewed 42,408 patients who received contrast from 3 institutions 
(18,749 were during stress echocardiography) with a matched control group 
of 15,989 patients (32). There was no significant difference in the rate of 
death or myocardial infarction between the contrast group and control group, 
both for resting and stress echocardiography. An online, web-based 
questionnaire conducted by Wei et at surveyed 13 centres and 78,383 doses 
of contrast (Definity®=66,164 and Optison™=12,219) administered to both in-
patients and out-patients during resting and stress echocardiography (14). 
The serious adverse event rate thought likely to contrast was 0.01%. These 
all occurred within 30 minutes of contrast administration. Anaphylaxis 
accounted for four of these reactions (0.005%). There were no serious 
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adverse events in any in-patients and there were no deaths reported following 
contrast administration. Herzog reported the adverse event rate in 16,025 
patients who received Definity® (12,974) or Optison™ (3051) in a single 
centre retrospective analysis (33). The total adverse event rate was 0.12%. 12 
patients developed transient severe back pain and 2 developed pruritis. 
Serious adverse events occurred in 0.031% and there were no deaths.  
 
In light of the increasing body of published work, contrast microspheres have 
a closely evaluated and well established safety profile. The recognised contra-
indications are: patients with known hypersensitivity to perflutren or 
hypersensitivity/contraindication to blood/blood products/albumin (if using 
Optison®), patients with known or suspected right to left, left to right or bi-
directional cardiac shunts and direct intra-arterial administration. Prior to 
administration, patients are advised of the 2% risk of headache, 1% risk of 
back/hip pain of flushing and the 1/10,000 chance of anaphylaxis. 
 
In routine daily clinical practice, complex clinical decisions are repeatedly 
made and choice of investigation based on risk and benefit analysis. None of 
these are usually made in isolation, without reference to competing factors. 
Consequently, the clinician must be cognisant that exposing a patient to a 
very small risk of an appropriate investigation is usually significantly 
outweighed by the benefit of a correct diagnosis and institution of appropriate 
therapy. As Grayburn eloquently states, there is a subtle but important 
difference between  “product safety” and “patient safety” and the two should 
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not be confused or used interchangeably (18). One could now also argue that 
the published evidence supports "product safety". 
 
Limitations of this work include it being a retrospective analysis of 
echocardiographic databases and thus is restricted by this study design. We 
also only assessed the acute safety (within 30 minutes of initiation of contrast 
administration) and have no data on mortality beyond this time frame or 
longer term side effects. There were no deaths within 30 minutes of contrast 
administration in this cohort. If an adverse event occurs following contrast 
administration, it typically will be within 30 minutes of administration. During 
the time period of data collection, the necessity for formal observation 
following contrast administration varied from no requirement, to all patients for 
30 minutes (October 2007), to “high risk” patients for 30 minutes (May 2008) 
and then back to no requirement (October 2011). 
 
Associated medical co-morbidities (other than left ventricular function, body 
mass index and right ventricular systolic pressures) were not statistically 
compared between the two groups in this analysis.  This would have helped in 
determining whether other specific patient groups are at higher risk of 
developing a contrast adverse reaction. The evidence to date suggests 
though that patients with greater co-morbidities are at no higher risk of 
developing an adverse reaction to those that are well. No data was collected 
during the study relating to the actual dose of contrast used.  However, the 
literature is not clear as to whether the likelihood of an adverse event is dose 
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related. This study would have been strengthened if we obtained this data to 
help clarify this issue.  
 
The actual numbers of patients who had a contrast adverse reaction was very 
low. Consequently, accurate statistical comparisons between groups may be 
difficult to interpret. This is especially so for comparing the RVSP between 
groups. However, the proportion that RVSP was measured in each group was 
nearly equivalent. Finally, due to the nature of stress induction during stress 
echocardiography, it may be difficult to determine whether an adverse event is 
due to contrast or the stressor. An example of this would be headache and 
flushing during a dobutamine stress echocardiogram. It is conceivable that 
these affects may be due to either the dobutamine or the contrast agent. This 
could then result in under-reporting of contrast adverse events if these are 
erroneously attributed to the dobutamine infusion, or vice versa. The clinician 
supervising the contrast study evaluated the adverse event and made a 
clinical judgement as to the most likely causality. However, as the adverse 
events were usually not clinically significant, typically did not affect test 
continuation and did not cause major morbidity or account for mortality, any 
possible incorrect causality labelling, from a pragmatic viewpoint, could be 
argued not to have a clinical impact on contrast usage. The commonest AR 
was back pain. Whilst this is a common symptom in many patient populations 
and possibly following exercise stress echocardiography (69.8% of patients in 
this analysis), the back pain due to contrast is distinct and typically not 
confused by the patient with their usual or mechanical back pain.  
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Conclusion 
 
The results of this multi-centre, retrospective analysis add to the evidence 
base that microsphere contrast echocardiography is a safe and very well 
tolerated investigation during rest and stress echocardiography, in a broad 
range of clinical indications. In this analysis, parameters that previously may 
have alerted the clinician to a higher risk of an adverse event (older age, 
hospitalised patient, higher BMI, lower LVEF and higher RVSP), did not 
increase the likelihood of having an adverse reaction.   
 
The recent American Society of Echocardiography consensus statement 
concluded with the comment “Contrast enhancement is an essential part of a 
modern, quality-driven echocardiography laboratory" (4). The ever expanding 
body of evidence describing the safety of contrast echocardiography should 
reassure the cardiology community and facilitate this incrementally beneficial 
investigation to be utilised appropriately.  
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Table 1:  Baseline patient and echocardiographic characteristics for all 
contrast echocardiograms. 
 Mean + SD 
Gender  Males 
   Females 
                   3545 (59.5%) 
2411 (40.5%) 
Age (years) 61.5 ± 13.4 (range 15-99) 
Body Mass Index (kg/m2) 29.4 ± 6.3 
LVEF (%) 58.3 ± 10.6 (range 4-85) 
RVSP (mmHg)#  36.0 ± 8.9 (range 27-100) 
Patient Location 
Out-patient 
In-patient 
 
5354 (88.9%)  
602 (11.1%) 
Study type 
Resting Transthoracic Echocardiogram 
Dobutamine Stress Echocardiogram 
Exercise Stress Echocardiogram 
 
1053 (17.7%) 
747(12.5%)  
 4156 (69.8%) 
Study Indication 
Functional stress testing  
Resting ventricular function  
Ventricular thrombus evaluation  
Ventricular morphology/mass  
Other  
 
4903 (82.3%) 
709 (11.9%) 
231 (3.9%)  
94 (1.6%) 
                       19 (0.3%) 
Contrast Administration 
             Diluted Bolus 
             Infusion 
 
5719 (96%) 
237 (4%) 
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#RVSP was obtained in 1844 (31%) contrast echocardiograms performed.  
LVEF = left ventricular ejection fraction. RVSP = right ventricular systolic 
pressure.  
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Table 2: Adverse Reactions. 
Adverse Reaction 
Number of 
patients (n=16) 
 
Back pain or hip pain  
 
10 
Non-life threatening anaphylaxis or rash  4 
Headache  1 
Transient speech difficulty or “stutter”  1 
Acute life threatening adverse events or severe anaphylaxis 0 
Deaths within 30 minutes of contrast administration 0 
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Table 3: Patient and echocardiographic characteristics of  those with adverse 
reactions. 
  Mean + SD 
 
Age (years) 
 
68.0 ± 12.7 (range 44-86)* 
Body Mass Index (kg/m2) 28.6 ± 4.7 (range 22-47)* 
LVEF (%) 58.1 ± 17.2 (range 39-70)* 
RVSP (mmHg)#  43.0 ± 6.9 (range 31-49)* 
Patient Location 
Out-patient 
In-patient 
 
13 
3 
 
* p = not significant 
# RVSP was only available in 5 patients who had an adverse event.  
LVEF = left ventricular ejection fraction. RVSP = right ventricular systolic 
pressure. 
 
 
 
 
 
 
 
